Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pfizer Buys Gene Therapy Startup in Deal Worth $700M

By Ryan Bushey | August 3, 2016

Pfizer’s interest in the promising gene therapy field continued Monday after the pharmaceutical firm revealed it bought Bamboo Therapeutics.

The deal is worth an estimated $700 million. Pfizer will acquire all of Bamboo’s assets upfront for $150 million with the option of additional milestone payments worth $495 million based on the success of the startup’s therapies as they progress through clinical development.

The Chapel Hill, North Carolina-based company is specializing in treatments for central nervous system disorders and neuromuscular conditions, reported Bloomberg.

Bamboo started patient enrollment for one trial testing its candidate for a nerve-cell disorder known as giant axonal neuropathy, which can inflict a gradual decline in mental function and movement due to malfunctioning nerve cells. Another therapy targeting Duchenne Muscular Dystrophy is also under development.

Overall, Pfizer will take control of the development process for these treatments and gain access to Bamboo’s 11,000-square-foot manufacturing facility where the company can monitor the production of these potent medicines.

Gene therapy is still an evolving field of healthcare. Its core principle is to repair defective genes that cause certain diseases by replacing them with new, healthy ones. Bamboo’s specialty is using a viral vector to deliver functioning genes to patients’ cells in an efficient manner, according to Bloomberg.

Pfizer has another partnership with Spark Therapeutics signifying the drug giant’s interest in this burgeoning field. It’s working with Spark on creating a gene therapy for Hemophilia B that was recently granted a Breakthrough Designation from the FDA.


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE